Derivatives benzothiazine

 

(57) Abstract:

Usage: new derivatives of benzothiazine are used as intermediates in the synthesis of occasionalcocaineuse drugs have anti-inflammatory activity. The inventive compounds produced by interaction of 1, 1-dioxide-N-(2-pyridyl)-4-hydroxy-2-methyl-2 N-1, 2-benzothiazine-3-carboxamide with etelcharge.com. table 1.

The invention relates to new chemical compounds derived benzothiazine responsible of General formula I

where R1lower alkyl WITH1-C4.

Known 6,6-dioxide-ocsinventory General formula II, where R2radical heteroaryl as anti-inflammatory and painkillers, in particular Droxicam (R2=2-pyridyl),

< / BR>
Studies have been conducted to obtain a simple and effective intermediates which would synthesize Droxicam in conditions, making it easy to obtain on an industrial scale.

You know getting Droxicam based on the ester of the formula III

where R3radical alkoxyl. In addition, the patent FR-2 597103 describes obtaining Droxicam based on compounds voiceskin compounds responsible of General formula 1 in which R1the radical is a lower alkyl (1-4 carbon atoms), can simplify the synthesis of Droxicam.

The compounds of formula I are obtained by reaction of compound III in which R3radical 2-pyridylamine, with the compound of General formula IV

Cl--O-R1where R1has the meaning given in relation to the General formula I, in the presence of a base.

The reaction between the compounds of General formulas III and IV occurs at a temperature of from -5 to 30aboutC for 1-5 hours Exact amounts of reactants entering the reaction are not critical, but it is however preferable to use at least 2 molar parts of a compound of formula IV per mole of the compounds of formula III for a more complete the reaction, as well as good yield.

The reaction is carried out in a medium of an organic solvent, selected from a number of pyridine, triethylamine, substituted pyridine, such as 4-dimethylaminopyridine, monomethyltin, dimethylpyridin; dimethylsulfoxide, dichloromethane, 1,2-dichloroethane, dimethylformamide, 1-2-dimethoxyethane, dioxane, tetrahydrofuran. In case of using a solvent which is not a base, it is necessary to add at the very the P CLASS="ptx2">

Alternative it is possible to conduct the reaction between the compounds of formulas III and IV in the presence of alkali metal hydride, for example sodium hydride, in organic solvents, such as dioxane, tetrahydrofuran, 1,2-dimethoxyethane, toluene, xylene, or dipolar aprotic solvents such as dimethylsulfoxide, dimethylformamide, hexamethylphosphoramide.

The reaction is carried out at the same temperature for the same time, as described for the case when we are talking about organic base.

In addition, new chemical compounds of General formula I, in which R1has values that can be transformed into Proximal formula II in which R2the radical is 2-pyridyl, heated in the organic solvent, such as pyridine, at 25-60aboutFor 5-24 h

These compounds of General formula 1 are thus used for the preparation of Droxicam. Furthermore, the new compounds exhibit anti-inflammatory activity.

The reaction leading to the formation of compounds of General formula 1 apparently occurs with the formation of the original organic salt or alkali metal salt, the anion which reacts with chloroform is the education connection, subject of the invention of General formula I. the Claim of the applicant but is not limited to this interpretation.

The reaction can be schematically represented as follows

< / BR>
The following examples of the preparation of derivatives of General formula 1 and obtain Droxicam, the General formula II (R2= 2-pyridine) based on derivatives of the General formula I.

P R I m e R 1. Obtaining 1,1-dioxide-N-etoxycarbonyl-N-(2-pyridyl)-4-ethoxycarbonyl-2-methyl-2H-12 - benzothiazin-3-carboxamide.

90 ml (0,945 mole) of ethylchloride added slowly to a suspension containing 75 g (0,226 mole) of 1,1-dioxide-N-(2-pyridyl)-4-hydroxy-2-methyl-2H-1,2-benzothiazin-3-carboxamid Yes in 225 ml of anhydrous pyridine at 0aboutAnd keep the temperature below 10aboutC. Stirring for 1 h, the temperature of the reaction medium reaches room temperature (approximately 20 theaboutC). Pour the suspension into 200 ml of ice water, stirred for 1 h at 0-5aboutC, filtered and washed with 200 ml of cold water.

The resulting product when active mixing is mixed with 200 ml of cold acetone, get 96.4 g (yield: 90%) of a white product with so pl. 144-146aboutC. By recrystallization with ethyl acetate floor is 6]

of 1.10(t, 3H), of 1.30 (t, 3H), 3,30 (s, 3H), 4,24 (g, 2H), 4,35 (g, 2H), 7,42 (m, 2H): 7,60 (m, 1H), 7,80 (m, 2H), of 7.96 (m, 2H), 8,53 (d, 1H)

IR (EHF): 1755, 1748, 1690, 1335, 1245, 1015, 715 cm-1.

P R I m m e R 2. Obtaining 1,1-dioxide-N-etoxycarbonyl-N-(2-pyridyl)-4-ethoxycarbonyl-2-methyl - 2H-1,2-benzothiazin-3-carboxamide.

2,62 g of 55% sodium hydride, suspended in mineral oil, washed with n-pentane to separate the oil by decantation. In the resulting sodium hydride (1.44 g to 0.06 mole) was added 100 ml of tetrahydrofuran in an ice bath with a temperature of 5aboutWith added 6.3 g (0,025 mol) of 1,1-dioxide-N-(2-pyridyl)-4-hydroxy-2-methyl-2H-1,2-benzothiazin-3-carboxamid Yes. Stirred for 1 h, keeping the temperature between 0 and 5aboutWith and add to 6.7 ml of 0.07 mole) of ethylchloride. Mix 1-2 hours before until the temperature reaches room temperature (20aboutWith), filtered, evaporated to the dry filter, washed with cold water to give 11.2 g (yield 94%). By recrystallization with ethyl acetate to obtain the product with so pl. 148-149aboutWith the spectroscopic characteristics of the same characteristics as specified in example 1.

P R I m e R 3. In conditions similar to those described in examples 1, 2, can be mentioned the following compounds using cootie-2-me-til-2H-1,2 benzothiazine-3-carboxamide, 1,1-dioxide-N-benzyloxycarbonyl-N-(2 - pyridyl)-4-benzyloxycarbonyl hydroxy-2-methyl-2H-1,2-benzothiazin-3-carboxamide 1,1-Dioxide-N-methoxycarbonyl-N-(2-pyridyl)-4-methoxycarbonylamino-2-methyl-2H-1,2-benzothiazin-3-carboxamide

P R I m e R 4. Getting 6,6-dioxide-5-methyl-3-(2-pyridyl)-2H,5H-1,3-oxazin [5,6-c][1,2]-benzothiazin-2,4-(3H)-dione to Droxicam.

Suspended 90 g (0,189 mol) of 1,1-dioxide, N-etoxycarbonyl-N-(2-pyridyl)-4-ethoxycarbonyl-2-methyl-2H-1,2-benzo - thiazin - 3-carboxamide in 150 ml of anhydrous pyridine. Heat the mixture to 35aboutC and maintained at this temperature for 15 hours Cooled to room temperature (20aboutC) and pour 750 ml of water. The precipitate is filtered, washed first with water, then acetone. So, get 64 g of product (yield: 95%). By recrystallization from 1,2-dichloromethane get a solid crystalline substance with a melting point 261-263aboutC.

Spectroscopic data: 1H-NMR, , [DMSO-d6]

to 3.02 ( 3H), 7,52 (m, 2H), 7,92 (m, 5H), charged 8.52 (d, 1H).

IR(EHF): 1185, 1355, 1410, 1640, 1710, 1790 cm-1.

Anti-inflammatory activity (inhibitor of runoff caused by carrageenan).

Was studied anti-inflammatory activity of the compounds obtained by the regional activity of phenylbutazone. Used the method described by Winter, with employees Proc. soc. (Exp. Biol. Med. 1982, 111, 544-547).

Calculated DA on the basis of the results obtained after 3 h after oral administration of the substance, and 2 h after injection carragenine in each paw with 0.1 ml of 2% aqueous solution carragenine subcutaneous route).

The results are shown in the table.

Below as examples of the three galouye form new compounds

An example of the composition of the capsules 1,1-Dioxide-N-etoxycarbonyl - N-(2-pyridyl)-4 - ethoxycarbonyl-2 - methyl - 2H-1,2 - benzothiazin-3 - carboxamide 0,020 g Lactose 0,136 g Talc 0,0016 g magnesium Stearate 0,0016 g Aerosil-200 0.0008 grams Weight capsules 0,160 g

An example of the composition of the tablets 1,1-Dioxide-N-atomichron - N-(2-pyridyl)-4-ethoxy - carbonyloxy-2-methyl - 2H-1,2-benzothiazin-3 - carboxamide 0,020 g Avicel pH 102 0,046 g Lactose to 0.055 g Primogel 0.003 g Polyvinylpyrrolidone 0.005 g magnesium Stearate to 0.011 g Mass of tablets 0,100 g Sample composition candles 1,1-Dioxide-N-ethoxy - carbonyl-N-(2-pyridyl)-4 - ethoxycarbonyl-2 - methyl - 2H-1,2-benzothiazin - 3-carboxamide 0,050 g Monolin 1,950 g Mass of candles 2,000 g

DERIVATIVES BENZOTHIAZINE General formula

< / BR>
where R1lower C1C4-alkyl, as a sub who enoy activity.

 

Same patents:

FIELD: chemistry.

SUBSTANCE: invention refers to cyclic sulphonamide derivatives of general formula I where bonds indicated with wavy lines represent mutually cis- in relation to cyclohexane ring; R3 represents H or hydrocarbon group having up to 10 carbon atoms; Ar1 and Ar2 independently represent phenyl which carries 0-3 substitutes independently selected from halogen, CF3, CHF2; or its pharmaceutically acceptable salt. Besides, invention refers to technology of compounds of general formula I and to pharmaceutical composition based on compounds of general formula I and applied as gamma-secretase inhibitor.

EFFECT: new derivatives of cyclic sulphonamide, activating gamma-secretase inhibition and suitable for treatment and prevention of Alzheimer's disease.

9 cl, 7 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed invention relates to novel compounds of formula (1) , in form of trans- or cis-isomers, or their mixture, where R1 is selected from , and ; R7 stands for lower alkyl; R8 stands for lower alkyl; X represents >C=O or >SO2; R9 and R11 represent hydrogen or together form double bond; R10 and R12 are independently selected from hydrogen or lower alkyl; m stands for 1 or 2; n stands for 0, 1 or 2 and their pharmaceutically acceptable salts. Invention also relates to pharmaceutical composition and to application of said compounds, as well as compounds of formula (I), where R1 represents (R2, R3, R4, R5 and R6 each is independently selected from hydrogen, lower alkyl, lower alkoxy group or halogen; on condition that R2, R3, R4, R5 and R6 do not represent hydrogen), for treatment and/or prevention of DPP-IV-associated diseases.

EFFECT: obtaining novel compounds for treatment and/or prevention of DPP-IV-associated diseases.

14 cl, 1 tbl, 33 ex

FIELD: chemistry.

SUBSTANCE: invention relates to 4-hydroxy-N-(2-carboxyphenyl)-1-methyl-2,2-dioxo-1H-2λ6 ,1-benzothiazine-3-carboxamide, which possesses diuretic activity.

EFFECT: obtained is novel compound, possessing useful biological activity.

1 tbl, 3 ex

FIELD: organic chemistry, heterocyclic compounds, medicine, pharmacy.

SUBSTANCE: invention relates to derivatives of heteroarylalkylpiperazine of the general formula (I):

wherein m = 1, 2 or 3; q means NH or oxygen atom (O); R1, R2, R3, R4 and R5 are taken independently among the group including hydrogen atom, (C1-C15)-alkyl, OR20 wherein R20 represents hydrogen atom; R6, R7 and R8 represent hydrogen atom; R9, R10, R11, R12, R13, R14, R15 and R16 are taken independently among the group including hydrogen atom, (C1-C4)-alkyl; or R9 and R10 in common with carbon atom to which they are joined form carbonyl group; R17 means heteroaryl that is taken among the group including indolyl, benzoxazolyl, benzothiazolyl, quinolinyl, isoquinolinyl, pyridyl, benzopyrazinyl substituted optionally with 1-2 substitutes taken among the group including hydrogen atom, CF3 group, (C1-C8)-alkyl, phenyl, CON(R20)2. Compounds elicit property as a partial inhibitor of oxidation of fatty acids and can be used in therapy for protection of skeletal muscles against results of muscular or systemic diseases. Also, invention describes a pharmaceutical composition based on the claimed compounds.

EFFECT: valuable medicinal properties of compounds.

39 cl, 3 tbl, 25 ex

FIELD: organic chemistry, pharmaceutical composition.

SUBSTANCE: new isoindoline-1-on-glucokinase activators of general formula I , as well as pharmaceutically acceptable salts or N-oxide thereof are disclosed. In formula A is phenyl optionally substituted with one or two halogen or one (law alkyl)sulfonyl group, or nitro group; R1 is C3-C9cycloalkyl; R2 is optionally monosubstituted five- or six-membered heterocyclic ring bonded via carbon atom in cycle to amino group, wherein five- or six-membered heteroaromatic ring contains one or two heteroatoms selected form sulfur, oxygen or nitrogen, one of which is nitrogen atom adjacent to carbon atom bonded to said amino group; said cycle is monocyclic or condensed with phenyl via two carbon atoms in cycle; said monosubstituted with halogen or law alkyl heteroaromatic ring has monosubstituted carbon atom in cycle which in not adjacent to carbon atom bonded to amino group; * is asymmetric carbon atom. Claimed compounds have glucokinase inhibitor activity and useful in pharmaceutical composition for treatment of type II diabetes.

EFFECT: new isoindoline-1-on-glucokinase activators useful in treatment of type II diabetes.

23 cl, 3 dwg, 43 ex

FIELD: pharmaceutical industry, medicine.

SUBSTANCE: invention relates to 5-membered N-heterocyclic compounds and salts thereof having hypoglycemic and hypolipidemic activity of general formula I , wherein R1 is optionally substituted C1-C8-alkyl, optionally substituted C6-C14-aryl or optionally substituted 5-7-membered heterocyclic group, containing in ring 1-4 heteroatoms selected from oxygen, sulfur and nitrogen; or condensed heterocyclic group obtained by condensation of 5-7-membered monoheterocyclic group with 6-membered ring containing 1-2 nitrogen atoms, benzene ring, or 5-membered ring containing one sulfur atom; { is direct bond or -NR6-, wherein R6 is hydrogen atom or C1-C6-alkyl; m = 0-3, integer; Y is oxygen, -SO-, -SO2- or -NHCO-; A ring is benzene ring, condensed C9-C14-aromatic hydrocarbon ring or 5-6-membered aromatic heterocyclic ring containing 1-3 heteroatoms selected from oxygen and nitrogen, each is optionally substituted with 1-3 substituents selected from C7-C10-aralkyloxy; hydroxyl and C1-C4-alkoxy; n = 1-8, integer; B ring is nitrogen-containing 5-membered heterocycle optionally substituted with C1-C4-alkyl; X1 is bond, oxygen or -O-SO2-; R2 is hydrogen atom, C1-C8-alkyl, C7-C13-aralkyl or C6-C14-aryl or 5-6-membered heterocyclic group containing in ring 1-3 heteroatoms selected from oxygen, sulfur and nitrogen, optionally substituted with 1-3 substituents; W is bond, C1-C20-alkylene or C1-C20-alkenylene; R3 is -OR8 (R8 is hydrogen or C1-C4-alkyl) or -NR9R10 (R9 and R10 are independently hydrogen or C1-C4-alkyl). Compounds of present invention are useful in treatment of diabetes mellitus, hyperlipidemia, reduced glucose tolerance, and controlling of retinoid-associated receptor.

EFFECT: new medicines for treatment of diabetes mellitus, hyperlipidemia, etc.

26 cl, 518 ex, 3 tbl

FIELD: organic chemistry.

SUBSTANCE: method relates to new method for production of 5-chloro-4-[(2-imidazoline-2-yl)amino]-2,1,3-benzothiadiazole hydrochloride of formula I . Claimed compound is high effective drug and is used in medicine as myorelaxant of central action. Claimed method includes condensation of N,N-dimethyldichloromethyleneammonium chloride with 5-chloro-4-amino-1,1,3-benzothiadiazole in organic solvent followed by treatment of formed alpha-chloroformamidine of formula R-N=C(Cl)N(CH3)2, wherein R is 5-chloro-2,1,3-benzothiazol-4-yl, with ethylenediamine. Formed intermediate of formula R-N=C(NH-CH2-CH2-NH2)N(CH3)2 is treated with hydrochloric acid, heated in organic solvent and 5-chloro-4-[(2-imidazoline-2-yl)amino]-2,1,3-benzothiadiazole hydrochloride of formula I is isolated.

EFFECT: simplified method for preparation of target compound directly in hydrochloride form.

FIELD: organic chemistry, chemical technology, agriculture.

SUBSTANCE: invention describes substituted azadioxocycloalkenes of the general formula (I): wherein A means unsubstituted or methyl-substituted dimethylene; Ar means unsubstituted or fluorine-substituted ortho-phenylene, thiophendiyl or pyridindiyl; E means group of the formula: wherein G means oxygen atom, groups -O-CH2-, -CH2-O- or -C(CH3)=N-O-CH2-; Z means unsubstituted or substituted phenyl, pyrimidinyl or thiadiazolyl, or naphthyl. Invention describes 4 methods for preparing compounds of the formula (I), 5 species of intermediate compounds used for preparing compounds of the formula (I), fungicide agents comprising compound of the formula (I) as an active substance, a method for preparing fungicide agents, method for control of harmful fungi using compound of the formula (I). Compounds of the formula (I) show fungicide properties and therefore they can be used in agriculture.

EFFECT: improved preparing methods, valuable properties of compounds.

13 cl, 5 tbl, 18 ex

FIELD: organic chemistry, pesticides, agriculture.

SUBSTANCE: invention relates to compounds that elicit high pesticide activity and can be used in control of pests of domestic and agricultural animals. Indicated compounds show the formula (I):

wherein R1 means halogen atom, (C1-C6)-halogenalkyl; R2 means hydrogen atom (H), (C1-C6)-alkyl, (C1-C6)-alkylene-phenyl; X1 means nitrogen atom (N); X2 means group C(CN); X3 means oxygen atom (O); Q means CH; R3 and R4 mean independently of one another hydrogen atom (H) or in common with carbon atom with which they are bound form (C3-C7)-cycloalkyl ring; R5 means a substitute taken among group including (C1-C6)-halogenalkyl, halogen atom being if m above 1 then substitutes R5 can be similar or different; m = 1, 2 or 3; n = 0 or 1. Also, invention describes a method for their preparing and method for control of pests.

EFFECT: valuable pesticide properties of compounds.

7 cl, 3 tbl, 14 ex

FIELD: organic chemistry, medicine, pharmacy.

SUBSTANCE: invention relates to biologically active compounds, in particular, to substituted 5R1,6R2-thiadiazine-2-amines and pharmaceutical compositions comprising thereof that can be used in medicine as potential pharmacologically active substances eliciting the unique combination of properties: expressed anticoagulant activity in combination with capacity to inhibit aggregation of platelets. Effect of these substances differ from preparations used in medicinal practice and they can be used therefore in treatment of such diseases as myocardium infarction, disturbance in cerebral circulation, rejection of transplanted organs and tissues and so on. Indicated compounds correspond to the formula (I):

wherein values of radicals R1, R2 and R3 are given in the invention claim.

EFFECT: valuable medicinal properties of compounds.

4 cl, 2 tbl, 7 dwg, 33 ex

FIELD: organic chemistry, chemical technology, medicine.

SUBSTANCE: invention relates to a method for preparing derivatives of indole of the general formula (I):

wherein R1 represents hydroxy-group; R2 represents hydrogen atom, (C1-C6)-alkyl, (C1-C6)-alkoxy-group, (C2-C6)-alkoxyalkyl or 4-methoxybenzyl; R3 represents hydrogen atom or (C1-C6)-alkyl; each among R4 and R represents independently hydrogen atom, (C1-C6)-alkyl or (C1-C6)-alkoxy-group; D represents an ordinary bond, (C1-C6)-alkylene, (C2-C6)-alkenylene or (C1-C6)-oxyalkylene; in the group-G-R6 wherein G represents an ordinary bond, (C1-C6)-alkylene; R represents saturated or unsaturated carbocyclic ring (C3-C15) or 4-15-membered heterocyclic ring comprising 1-5 atoms of nitrogen, sulfur and/or oxygen wherein this ring can be substituted. Also, invention describes a method for preparing derivatives of indole and DP-receptor antagonist comprising derivative of the formula (I) as an active component. As far as compounds of the formula (I) bind with DP-receptors and they are antagonists of DP-receptors then they can be useful for prophylaxis and/or treatment of diseases, for example, allergic diseases.

EFFECT: improved preparing method, valuable medicinal properties of compounds.

11 cl, 7 tbl, 353 ex

FIELD: pharmaceutical chemistry, medicine.

SUBSTANCE: invention relates to substituted pyridines and pyridazines with angiogenesis inhibition activity of general formula I

(I)1, wherein ring containing A, B, D, E, and L represents phenyl or nitrogen-containing heterocycle; X and Y are various linkage groups; R1 and R2 are identical or different and represent specific substituents or together form linkage ring; ring J represents aryl, pyridyl or cycloalkyl; and G's represent various specific substituents. Also disclosed are pharmaceutical composition containing claimed compounds, as well as method for treating of mammalian with abnormal angiogenesis or treating of increased penetrability using the same.

EFFECT: new pyridine and pyridazine derivatives with angiogenesis inhibition activity.

26 cl, 6 tbl, 114 ex

FIELD: organic chemistry, herbicides, agriculture.

SUBSTANCE: invention elates to novel derivatives of uracil of the formula [I] possessing herbicide activity, a herbicide composition based on thereof and to a method for control of weeds. In derivatives of uracil of the formula [I] the group Q-R3 represents a substituted group taken among:

wherein a heterocyclic ring can be substituted with at least a substitute of a single species taken among the group involving halogen atom, (C1-C6)-alkyl-(C1-C6)-alkoxy; Y represents oxygen, sulfur atom, imino-group or (C1-C3)-alkylimino-group; R1 represents (C1-C3)-halogenalkyl; R2 represents (C1-C3)-alkyl; R3 represents OR7, SR8 or N(R9)R10; X1 represents halogen atom, cyano-group, thiocarbamoyl or nitro-group; X2 represents hydrogen or halogen atom wherein each among R7, R8 and R10 represents independently carboxy-(C1-C6)-alkyl and other substitutes given in the invention claim; R9 represents hydrogen atom or (C1-C6)-alkyl. Also, invention relates to intermediate compounds used in preparing uracil derivatives.

EFFECT: improved preparing method, valuable properties of compounds.

40 cl, 16 sch, 12 tbl, 65 ex

Up!